Lilly, Metis agree drug-delivery collaboration with milestone payments of up to about $1.1 billion
Key Facts
Metis TechBio announced a collaboration agreement with Eli Lilly on October 19, 2026, to develop drug-delivery technologies, making it eligible for milestone payments of up to about $1.1 billion, according to a company statement. The payments depend on reaching development, regulatory and commercial milestones during the collaboration. They come in addition to an upfront payment that Metis described as being in the low tens of millions of U.S. dollars. The financial terms also include tiered royalties on products resulting from the collaboration, according to Reuters. These royalties are calculated as a single-digit percentage of the products' annual net sales. The disclosed financial consideration thus combines an initial payment, payments tied to development, regulatory and commercial progress, and sales-linked returns.
The collaboration focuses on researching and developing solutions to deliver drugs to specific tissues using lipid nanoparticles, according to Reuters' report on the agreement. The joint work aims to improve tissue-targeting precision, potentially improving the therapeutic performance of products using these technologies. The collaboration's intended capabilities include applying delivery solutions across multiple disease areas, according to the same report. Lilly will contribute its expertise in drug discovery, development and commercialization, according to Metis' statement announcing the agreement. Metis' work will draw on its proprietary platform for discovering and optimizing ionizable lipids using artificial intelligence. Its chairman and chief executive, Chris Lai, said in the statement that "drug delivery remains a critical factor in therapeutic success."
Metis says in its description of its technology infrastructure that its library contains more than 10 million ionizable lipids for lipid nanoparticles. Its lipid discovery platform uses predictive artificial intelligence alongside molecular dynamics models among the tools the company employs in this field. According to the company, the platform predicts more than 20 lipid properties as part of its discovery and optimization work. Its screening system also combines a high-throughput platform, in-house animal models and AI-guided screening workflows. Metis uses these tools to accelerate and improve in vivo data collection, according to its technology platforms page. This approach combines computational prediction, high-throughput screening and animal-model testing in the company's work on lipid nanoparticles.
The Lilly collaboration is part of Metis' partnership activity, which previously included a long-term strategic agreement with Luye Pharma, according to the company's announcement of that collaboration. The earlier agreement was signed in Beijing to develop AI-powered drug delivery. In capital markets, Metis TechBio listed on the Hong Kong Stock Exchange on May 13, 2026, under the ticker 7666.HK. In announcing the listing, the company described its business as focused on innovation in AI-powered nanodelivery. Lilly's agreement with Metis was preceded by another drug-discovery collaboration with Insilico, according to a report published by Investing.com on March 30, 2026. The report said the potential total value of that agreement was up to $2.75 billion.
In its half-year results, Metis reported revenue of 154.3 million yuan, up 13,399% from the corresponding period a year earlier, according to its results statement. The company added that half-year revenue exceeded revenue for the whole of 2025 by 47%, providing another comparison of the scale of its business alongside the annual growth rate. In the same period, its adjusted net loss narrowed by 56.4% to 51.1 million yuan, according to the statement. The results also showed research and development expenses rising 48.1% year on year. Those expenses totaled 172.4 million yuan during the half-year period covered by the company's announcement. The increase in research spending thus coincided with revenue growth and a narrower adjusted net loss, while the company continued to post a loss on that basis.
In the next phase of the collaboration, Metis and Lilly will research and develop tissue-targeted drug-delivery technologies, according to the agreement's announced scope. The work aims to improve targeting specificity and therapeutic performance, with potential applications across multiple disease areas, according to Reuters. Potential payments to Metis are tied to progress through the development, regulatory and commercial milestones included in the agreement. Royalties are also linked to annual net sales of products resulting from the collaboration, according to the disclosed terms. For Lilly's upcoming financial disclosures, the company set the date for announcing its third-quarter 2026 results in a notice to investors. Those results are scheduled for release on October 29, 2026, according to Eli Lilly's announcement.